Esperion Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €996.83M +107.5% €545.33M +222.2% 54.7% +0.19 pp N/A N/A
    (estimated) €480.38M +40.2% €169.25M +318.5% 35.2% +0.23 pp N/A N/A
    (estimated) €342.68M +17.6% €40.44M -1,553.5% 11.8% +0.13 pp €54.40M +176.3% 15.9% +0.091 pp
    (estimated) €291.34M -7.3% -€2.78M -80.8% -1.0% +0.037 pp €19.69M -90.6% 6.8% -0.60 pp
    (estimated) €314.37M +10.5% -€14.50M -67.3% -4.6% +0.11 pp €208.89M -1,145.5% 66.4% +0.73 pp
    €284.49M +185.7% -€44.30M -75.3% -15.6% +1.6 pp -€19.98M -82.8% -7.0% +1.1 pp
    €99.59M +54.1% -€179.14M -27.3% -179.9% +2.0 pp -€115.99M -22.5% -116.5% +1.2 pp
    €64.61M -3.8% -€246.40M -9.7% -381.3% +0.25 pp -€149.67M -33.7% -231.6% +1.0 pp
    €67.16M -65.5% -€272.94M +91.8% -406.4% -3.3 pp -€225.84M +267.4% -336.3% -3.0 pp
    €194.80M +53.4% -€142.27M +52.4% -73.0% +0.0045 pp -€61.47M +3.5% -31.6% +0.15 pp
    €127.01M -19.6% -€93.33M -46.0% -73.5% +0.36 pp -€59.40M -53.3% -46.8% +0.34 pp
    €157.93M +∞% -€172.77M +20.9% -109.4% -1.1 pp -€127.12M +13.1% -80.5% -0.80 pp
    €0.00 +NaN% -€142.96M +122.7% N/A -€112.39M +175.6% N/A
    €0.00 +NaN% -€64.19M +50.6% N/A -€40.78M +25.9% N/A
    €0.00 +NaN% -€42.62M +36.9% N/A -€32.39M +21.5% N/A
    €0.00 -100.0% -€31.14M +39.4% N/A -€26.67M +72.3% N/A
    €4.26B +∞% -€22.33M +122.2% -0.5% -0.0052 pp -€15.48M +67.4% -0.4% -0.0036 pp
    €0.00 +NaN% -€10.05M +8.5% N/A -€9.25M +19.6% N/A
    €0.00 +NaN% -€9.26M -62.3% N/A -€7.73M -64.4% N/A
    €0.00 +NaN% -€24.59M +15.2% N/A -€21.75M +22.5% N/A
    €0.00 -100.0% -€21.34M -9.6% N/A -€17.76M +24.9% N/A
    €1.71K +∞% -€23.61M +158.4% -1,378,800.0% -14K pp -€14.22M +164.1% -830,650.0% -8.3K pp
    €0.00 -€9.13M N/A -€5.38M N/A

    Notifications